GlassScriptPhysician profile
Stephanie Symonds
NPI 1457721540
$2,240.88
in general payments reported to CMS, 2019-2025
21 companies · $22.92 in 2025
The $22.92 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $776 · 2023: $578 · 2024: $731 · 2025: $22.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.09 | 2022-2024 | |
| Tempus Ai, INC | $322.21 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $221.45 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $214.93 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $173.91 | 2022-2023 | Spravato, Invega Trinza, Invega Sustenna |
| Corium, LLC | $158.50 | 2021-2024 | Azstarys |
| Noven Therapeutics, LLC | $107.94 | 2023-2024 | Xelstrym, Secuado |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.88 | 2022-2024 | Caplyta |
| Alkermes, INC. | $105.34 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $91.85 | 2022-2023 | Austedo, Uzedy, Austedo Xr |
| Glaxosmithkline, LLC. | $56.61 | 2024-2025 | Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $29.19 | 2022 | |
| Lundbeck LLC | $22.29 | 2022 | |
| Merck Sharp & Dohme LLC | $20.72 | 2022 | |
| Tris Pharma INC | $20.70 | 2023 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $18.24 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.21 | 2022 | |
| Neos Therapeutics, LP | $16.07 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.98 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.10 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $13.67 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Symonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.